Pranib 100mg, containing Pralsetinib, is an advanced cancer therapy manufactured by Pharma Lord. Pralsetinib is a selective RET (rearranged during transfection) inhibitor used for the treatment of specific cancers driven by RET gene mutations or fusions. This includes certain types of non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other RET-altered thyroid cancers. By targeting the abnormal RET proteins that fuel cancer growth, Pranib offers a precise, targeted treatment option for patients with RET-driven tumors.
Advantages:
- Targeted Therapy for RET Mutations: Pranib is specifically designed to inhibit RET gene mutations and fusions, making it a highly effective treatment for patients with cancers driven by these alterations.
- Broader Application Across Cancer Types: It is used in the treatment of non-small cell lung cancer (NSCLC) and RET-mutant thyroid cancers, including medullary thyroid cancer (MTC), providing flexibility across different cancers.
- Potential for Improved Outcomes: Clinical studies have shown that Pralsetinib can significantly shrink tumors and slow disease progression, leading to better outcomes in patients with RET-driven cancers.
- Reduced Side Effects Compared to Chemotherapy: As a targeted therapy, Pranib is designed to affect cancer cells with RET alterations while minimizing damage to normal cells, leading to fewer side effects compared to traditional chemotherapy.
Uses:
- Treatment of RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.
- Treatment of RET-mutant medullary thyroid cancer (MTC) in patients requiring systemic therapy.
- Treatment of RET fusion-positive thyroid cancer in patients who require systemic therapy and are refractory to radioactive iodine (if appropriate).
Pranib 100mg provides a critical option for cancer patients whose tumors are driven by RET gene alterations, offering a more precise and potentially more effective treatment compared to conventional therapies.